JCM
CLDX icon

Jacobi Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Jacobi Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$8K – 1387
2021
Q1 		$8K Buy
+400
New +$9.19K ﹤0.01% 1020

Other funds holding CLDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Jacobi Capital Management's CLDX Position: Q2 2021 in Review

Jacobi Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2021, closing a stake of 400 shares — an estimated $8K sold.

Jacobi Capital Management first reported a position in CLDX in Q1 2021 and held it in 1 quarter. The position peaked at $8K in Q1 2021. 131 funds tracked by Wall St. Rank hold CLDX as of Q2 2021.

  • Jacobi Capital Management reported no remaining Celldex Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 400 Celldex Therapeutics shares in Q2 2021, an estimated $8K.
  • Jacobi Capital Management first reported a position in Celldex Therapeutics in Q1 2021 and held it in 1 quarter.
  • Jacobi Capital Management's Celldex Therapeutics position peaked at $8K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2021.

Based on Jacobi Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.